Working… Menu

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02906397
Recruitment Status : Active, not recruiting
First Posted : September 20, 2016
Last Update Posted : February 5, 2021
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).

Condition or disease Intervention/treatment Phase
ADVANCED HEPATOCELLULAR CARCINOMA (HCC) Drug: Galunisertib 150mg by mouth twice a day Radiation: Stereotactic Body Radiotherapy (SBRT) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
Actual Study Start Date : March 30, 2017
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Arm Intervention/treatment
Experimental: Experimental: Galunisertib/SBRT
Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
Drug: Galunisertib 150mg by mouth twice a day
on days 1-14 of 28 day cycles
Other Name: LY2157299

Radiation: Stereotactic Body Radiotherapy (SBRT)
18GY delivered in one fraction between C1D15 and C1D28

Primary Outcome Measures :
  1. Safety based upon standard laboratory and clinical adverse event monitoring [ Time Frame: Cycle 1 Day 15 through date of progression assessed up to 90 months ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4

Secondary Outcome Measures :
  1. Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls. [ Time Frame: Cycle 1 Day 15 through date of progression assessed up to 90 months ]
    From Cycle 1 Day 1 to progression of disease

  2. Response rate [ Time Frame: Cycle 3 Day 1 and every 8 weeks thereafter up to 90 months ]
    by conventional CT and MRI

  3. Overall survival (OS) [ Time Frame: Cycle 1 Day 1 to death due to any cause or last patient contact alive up to 90 months ]
    start of treatment to death due to any cause or last patient contact alive

  4. Inhibition of TGF-β signaling by intervention as evidenced by downstream changes in this pathway [ Time Frame: Cycle 1 Day 15 through date of progression assessed up to 90 months ]
  5. Promotion of anti-tumor immunity with addition of intervention to SBRT [ Time Frame: Cycle 1 Day 15 through date of progression assessed up to 90 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated due to disease extension, co-morbidities or other technical reasons)
  • ≥18 years of age and ability to understand and the willingness to sign a written informed consent document. A legally authorized representative signature in the event that the subject is not able to sign themselves is permitted.
  • Patients must have either not been eligible for sorafenib therapy, have failed sorafenib therapy, have discontinued sorafenib therapy due to intolerable toxicity or have refused sorafenib
  • ECOG performance status ≤2
  • Childs Pugh score of ≤7
  • Life expectancy of at least 12 weeks
  • Must be able to swallow tablets
  • Must be willing to comply with protocol procedures (including completion of diaries and outcome measures)
  • Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) must have been completed ≥4 weeks prior to enrollment
  • Must be willing to undergo a pretreatment biopsy
  • A history of prior radiotherapy is permitted, as long as the prior radiated site is not overlapping with the site of planned SBRT
  • Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • An index lesion measuring between 1cm-10cm that is amenable to hypofractionated radiation therapy at the discretion of the treating radiation oncologist
  • Women of childbearing potential must have a negative serum pregnancy test performed at screening
  • Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device) which has an expected failure rate of <1%, if appropriate for at least 3 months after the last dose of galunisertib.

Patients who are HIV-positive are eligible if:

  • CD4+ cell count is greater or equal to 250cells/mm3.
  • If patient is on retroviral therapy, there must be minimal interactions or -overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment.
  • No history of non-malignancy AIDS defining conditions other than low CD4+ count.
  • Probable long-term survival with HIV if cancer were not present.
  • Must have adequate organ and hematopoietic function as defined below:

Laboratory Test Required Value Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100 x 10^9/L Hemoglobin ≥9.0 x 10^9/L Alanine transaminase ≤2.5 x ULN Aspartate aminotransferase ≤2.5 x ULN Serum creatinine or CrCl ≤2.0 x ULN Total Bilirubin ≤1.5 x ULN

Exclusion Criteria:

  • Any history of a serious medical or psychiatric condition that would prevent the patient from signing the informed consent form
  • Pregnant or breastfeeding women.
  • Use of any other chemotherapy, radiotherapy or experimental drug within 4 weeks prior to first study treatment date
  • A history of radiotherapy that, in the opinion of the investigator, would render SBRT unsafe to administer
  • Those who have not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date, with the exception of stable grade 2 neuropathy
  • Subjects may not receive concomitant anticancer agents. Antiviral agents aimed at treating infectious hepatitis are permitted
  • History of or suspected hypersensitivity to radiation or to galunisertib
  • Uncontrolled ascites
  • Subjects with a history of or evidence of cardiac disease during screening, defined as any one of the following: myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, uncontrolled hypertension.
  • Subjects with a documented major ECG abnormalities (not responding to medical treatments) or not clinically stable for at least 6 months.
  • Subjects with major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months.. Note: Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal).
  • Subjects with a predisposition toward developing aneurysms of the ascending aorta or aortic stress including a family history of aneurysms, Marfan Syndrome, Ehlers Danlos Type IV, bicuspid aortic valve or evidence of damage to the large vessels of the heart documented by previously obtained or screening CT scan/MRI
  • Subjects with uncontrolled brain metastases. Subjects with brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study treatment and must be off steroids
  • Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low-dose methotrexate). All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment
  • Active drug or alcohol use or dependence as documented in the chart that, in the opinion of the investigator, would interfere with adherence to study requirements
  • A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results
  • Prior malignancies. Patients with carcinoma in-situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.
  • Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint
  • Any other conditions judged by the investigator that would limit the evaluation of the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02906397

Layout table for location information
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Layout table for investigator information
Principal Investigator: Kim Reiss Binder, MD Abramson Cancer Center of the University of Pennsylvania
Layout table for additonal information
Responsible Party: University of Pennsylvania Identifier: NCT02906397    
Obsolete Identifiers: NCT03081377
Other Study ID Numbers: 826247 (UPCC 24216)
First Posted: September 20, 2016    Key Record Dates
Last Update Posted: February 5, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases